AUTHORS
Madison Gil, Konstantine Halkidis, MD,PhD2, X. Long Zheng, MD, PhD3
AFFILIATIONS
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 University of Kansas Medical Center, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background: During normal hemostasis, the plasma metalloprotease ADAMTS13 (A Disintegrin and Metalloproteinase with ThromboSpondin type 1 motifs, family member 13) cleaves ultra-large multimers of von Willebrand Factor (vWF) to regulate its platelet adhesion activity. This critical function is impaired in thrombotic thrombocytopenic purpura (TTP), a disorder characterized by a severe deficiency in ADAMTS13 activity. In immune TTP (iTTP), which comprises most clinical cases, autoantibodies against ADAMTS13 are developed that render the enzyme nonfunctional, resulting in aberrant microthrombi formation that can have potentially fatal consequences. Although central to iTTP pathophysiology, the mechanisms underlying the autoantibody-mediated inhibition of ADAMTS13 are not completely understood. The spacer domain of ADAMTS13, a crucial exosite for vWF binding, is the main target for most inhibitory antibodies identified in iTTP. A loop in the ADAMTS13 spacer domain denoted as “motif B” is well-conserved across species but not for other ADAMTS family members, suggesting this structural element is essential for the specific function of the enzyme.
Objective: Our goal is to investigate the involvement of motif B (L632-R639) in ADAMTS13 protease activity and antibody binding at single amino acid resolution.
Methods: We performed site-directed mutagenesis to substitute residues in motif B and generate recombinant ADAMTS13 variants via a HEK293 cell expression system. Enzymatic activity of the variants was measured using the surrogate peptidyl substrate, FRETS-VWF73, which exhibits increased fluorescence upon cleavage. Susceptibility to inhibition was evaluated by examining residual activity when an iTTP patient-derived antibody is present. The most promising variants were further analyzed for antibody resistance by titrating with the antibody to assess any differences in half-maximal inhibitory concentration (IC50) and conducting coimmunoprecipitation assays to determine antibody binding capacity. To enhance physiological relevance, the ability to cleave multimeric vWF was determined using a vWF multimer cleavage assay and microfluidic shear-based system.
Results: Deletion of motif B or a significant portion of it essentially resulted in complete loss of proteolytic activity. In contrast, multiple amino acid substitution variants retained appreciable enzymatic activity comparable to the wildtype protein. However, most motif B variants lost their activity in the presence of a patient-derived inhibitory monoclonal antibody, indicating that they are still susceptible to inhibition. Interestingly, one of the variants (E634Q/D635N/M5) acquired significant resistance, with only ~30% inhibition observed. Titration of the E634Q/D635N/M5 variant with antibody revealed a substantial increase (~950-fold) in the IC50 value compared to wildtype ADAMTS13. Furthermore, a binding interaction between the antibody and E634Q/D635N/M5 was unable to be detected in a pull-down assay. Under both denaturing conditions and under shear, E634Q/D635N/M5 was observed to have the capacity to cleave multimeric vWF.
Conclusions: Motif B in the ADAMTS13 spacer domain is important for the function of the enzyme, as deletion in its entirety results in a catalytically dead protein. Selective modification of the residues in motif B has allowed us to identify a novel ADAMTS13 variant that preserves proteolytic activity towards vWF while gaining significant resistance to antibody-mediated inhibition. This antibody-resistant variant could have potential as an effective therapeutic agent for iTTP treatment.
DISCLOSURES
Madison Gil: No relevant conflicts of interest to declare.